

1 **Effect of Smoking on Pathological Grade and Stage in Clinically Low-Risk Patients**

2 **Ercan Öğreden\*, Ural Oğuz, Erhan Demirelli, Orhan Yalçın**

3 Giresun University, Faculty of Medicine, Department of Urology, Giresun, Turkey

4 **\*Corresponding Author:** Ercan Ogreden

5 **E mail:** ercanogreden@gmail.com

6 **Mobile Tel:** +9 0 505 896 3960

7 **Correspondence Address:** Giresun University, Faculty of Medicine, Department of Urology.

8 P.C: 28200, Giresun, Turkey.

9 **Abstract**

10 We investigated the effect of cigarette smoking on pathological staging in clinically low-risk  
11 patients. Data of 59 patients who were diagnosed with bladder tumor for the first time and had  
12 a single lesion radiologically and endoscopically smaller than 3 cm were investigated  
13 retrospectively. 33 patients who smoked were classified as Group I, and 26 patients who did  
14 not smoke were classified as Group II. Pathological diagnoses of the patients in both groups  
15 were compared. The mean age of the patients were 64.8 (20–86) years. In Group II, 5 (19.2%)  
16 were female and 21 (80.8%) were male ( $p < 0.05$ ). Nine patients (27.3%) in Group I and 18  
17 patients (69.2%) in Group II had Ta disease ( $p < 0.05$ ). Nineteen patients (57.6%) in Group I  
18 and 5 patients (19.2%) in Group II had T<sub>1</sub> disease ( $p < 0.05$ ). The number of patients with low  
19 grade (LG) tumor were 8 (24.2%) and 19 (73.1%) in Group I and in Group II, respectively ( $p$   
20  $< 0.05$ ). The number of patients with high grade(HG) tumor were 25 (75.8%) and 7 (26.9%)  
21 in Group I and in Group II, respectively ( $p < 0.05$ ). TaHG was detected in 9 (27.3%) patients  
22 in Group I. In contrast, no patients in Group II had TaHG disease ( $p < 0.05$ ). The number of

23 patients with T<sub>1</sub>HG was 17(51.5%) patients in Group I and 2 (7.69%) patients in Group II (p  
24 < 0.05). Smoking is associated with pathologically HG and stage in patients with first time  
25 bladder tumor which is single and smaller than 3 cm.

26 **Keywords:** Smoking; Pathologic stage; Pathologic grade; Low risk

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48 **1. Introduction**

49 The bladder is the most common site for cancer in urinary system. Bladder cancer is the  
50 fourth most common type of cancer in men following prostate, lung, and colorectal cancers  
51 [1]. In bladder cancer, male/female ratio is 3.5:1 worldwide [2]. Association of smoking habit  
52 with bladder tumor has been well known. Smoking is the worst risk factor for bladder cancer  
53 and increases the risk of bladder cancer by 2 to 4 times [3]. Molecular changes associated  
54 with bladder cancer are crucial in determining the prognosis. The most important prognostic  
55 factor for bladder cancer is the pathological stage and the degree of tumor determined by  
56 histopathological examination [4]. Bladder cancer in patients who smoke and have a non-  
57 muscle-invasive disease is associated with advanced tumor stage and grade [5]. However,  
58 studies investigating the effect of smoking on stage and grade in clinically low-risk patients  
59 with bladder tumors that are smaller than 3 cm are limited. The aim of this study was to  
60 discuss the effect of cigarette smoking on pathological staging in patients with clinically low-  
61 risk bladder cancer.

62

63

64

65

66

67

68

69

70

71 **2.Materials and Methods**

72 The files of 154 patients who were diagnosed with bladder cancer for the first time between  
73 2009 and 2013 were retrospectively reviewed in our clinic. Fifty-nine first-time patients with  
74 a single lesion, radiologically and endoscopically smaller than 3 cm in diameter were included  
75 in the study. Patients who were diagnosed with carcinoma in situ (CIS) in pathology  
76 specimens were excluded. Age at first diagnosis, smoking status, stage and grade of primary  
77 tumor, tumor diameter and number were noted documented. Patients who actively smoke  
78 cigarette were designated as Group I and lifetime non-smokers were designated as Group II.  
79 Group I was consisted of 33 patients and group II had 26 patients. Pathological diagnoses of  
80 the patients in both groups were compared. The grading of the samples was performed  
81 according to the World Health Organization (WHO) system in 1973 and the staging was  
82 performed according to Cancer Staging System of the 2002 American Cancer Staging  
83 Commission (AJCC).

84 All procedures performed in studies involving human participants were in accordance with  
85 the ethical standards of the institutional and/or national research committee and with the 1964  
86 Helsinki Declaration and its later amendments or comparable ethical standards.

87 **2.1.Statistical Analysis**

88 The data obtained in this study were analyzed with the SPSS 20 package program. Shapiro  
89 Wilk test was used while investigating the normal distribution of variables because of the unit  
90 numbers. The results were interpreted using significance level of 0.05. In the case of  $p < 0.05$ ,  
91 it is stated that the variables do not come from the normal distribution, whereas in the case of  
92  $p > 0.05$ , the variables were said to come from the normal distribution.

93

### 94 3.Results

95 The mean age of the patients were 66.4 (30-86) years and 62.7 (20-84) years, respectively (p  
96 = 0.427) (Table-1). All patients were male in Group I, while 5 (19.2%) were female and 21  
97 (80.8%) were male in Group II (p <0.05). (**Table-1**)

98 The number of patients with pathologic stage Ta was 9 (27.3%) in Group I and 18 (69.2%) in  
99 Group II (p <0.05) (P <0,05). In the non-smoker group, the rate of detection of Ta tumor was  
100 significantly higher whereas the rate of detection of T1 tumor was significantly higher in  
101 smokers (p <0,05). Pathological T2 tumor rates were equally distributed in both groups (p =  
102 1).

103 The number of patients with low grade tumor was 8 (24,2%) in group I and 19 (73,1%) in  
104 group II (p <0,05). The number of patients with high grade tumor was 25 (75,8%) and 7  
105 (26,9%), respectively (p <0,05). It was found that cigarette smoking increased the grade of  
106 tumor. (Table-2)

107 When pathological grade and grade distributions of the groups are evaluated together; the  
108 number of Ta low grade patients was 11 (33,3%) and 15 (57,7%) in Group I and Group II  
109 respectively, while Ta high grade patients were 9 (27,3%) in Group I and zero in Group II.  
110 Smoking was not associated with low grade pathological stage (p = 0,108), and it was found  
111 to increase the risk of Ta high grade (p <0,05).

112 The number of patients with T1 low grade was 2 (6.1%) in Group I and 3 (11.54%) in Group  
113 II. However, the result was not statistically significant (p = 0.646). The number of patients  
114 with T1 high grade was 17 (51.5%) in Group I and 2 (7.69%) in Group II (p <0,05). It was  
115 found that smoking was associated with high grade in Ta and T1 stage tumors.

116 It was determined that association of smoking with tumor stage and grade in the muscle-  
 117 invasive bladder tumors was similar to that of non-smokers ( $p=1$ ). (**Table-2**)

118 **Table 1.**

								Mann Whitney U Test		
		n	Mean	Median	Min	Max	ss	Rank Avg.	z	p
Age	Group I	33	66,4	69	30	86	12,62	31,58	-0,795	0,427
	Group II	26	62,7	65,5	20	84	14,74	28		
	Total	59	64,8	68	20	86	13,6			

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140 **Table 2.**

		Group I		Group II		Total			
		n	%	n	%	n	%	Chi Square Test	p
Gender	Female	0	0	5	19,23	5	8,5	Fisher's exact	0,013
	Male	33	100	21	80,77	54	91,5		
	Total	33	100	26	100	59	100		
Ta	Absent	24	72,7	8	30,77	32	54,2	8,693	0,003
	Exist	9	27,3	18	69,23	27	45,8		
	Total	33	100	26	100	59	100		
T <sub>1</sub>	Absent	14	42,4	21	80,77	35	59,3	7,343	0,007
	Exist	19	57,6	5	19,23	24	40,7		
	Total	33	100	26	100	59	100		
T <sub>2</sub>	Absent	28	84,9	23	88,46	51	86,4	Fisher's exact	1
	Exist	5	15,2	3	11,54	8	13,6		
	Total	33	100	26	100	59	100		
Grade	LG	8	24,2	19	73,08	27	45,8	12,074	0,001
	HG	25	75,8	7	26,92	32	54,2		
	Total	33	100	26	100	59	100		
TaLG	Absent	22	66,7	11	42,3	33	55,9	2,6	0,108
	Exist	11	33,3	15	57,7	26	44,1		
	Total	33	100	26	100	59	100		
TaHG	Absent	24	72,7	26	100	50	84,7	Fisher's exact	0,003
	Exist	9	27,3	0	0	9	15,3		
	Total	33	100	26	100	59	100		
T <sub>1</sub> LG	Absent	31	93,9	23	88,46	54	91,5	Fisher's exact	0,646
	Exist	2	6,1	3	11,54	5	8,5		
	Total	33	100	26	100	59	100		
T <sub>1</sub> HG	Absent	16	48,5	24	92,31	40	67,8	10,863	0,001
	Exist	17	51,5	2	7,69	19	32,2		
	Total	33	100	26	100	59	100		
T <sub>2</sub> LG	Absent	32	97,0	25	96,15	57	96,6	Fisher's exact	1
	Exist	1	3,0	1	3,85	2	3,4		
	Total	33	100	26	100	59	100		
T <sub>2</sub> HG	Absent	29	87,9	23	88,46	52	88,1	Fisher's exact	1
	Exist	4	12,1	3	11,54	7	11,9		
	Total	33	100	26	100	59	100		

141 **LG:low grade, HG:high grade**

142

143

144

145

146 **4.Discussion**

147 Occupational exposure and smoking are two important risk factors for developing bladder  
148 cancer. Occupational exposure of bladder carcinogens (2-naphthylamine, benzidine, 4-  
149 aminobiphenyl, etc.) are associated with the stage and grade of the disease. Tobacco contains  
150 more than 60 carcinogens, including benzidine derivatives and aromatic amines, as well as  
151 occupational exposure. These substances have an important role in bladder cancer. In  
152 addition, studies have shown that high-grade bladder tumors develop more often in people  
153 with high-risk occupations [6-8]. It is also known that cigarette smoking increases the risk of  
154 recurrence and progression of non-muscle-invasive bladder cancer (NMIBC) [9]. The  
155 association of cigarette smoking with bladder cancer has been known for 60 years and  
156 accounts for about 50% of cases [10].

157 Two main mutation pathways are responsible for bladder cancer development. One of these is  
158 the fibroblast growth factor receptor-3 (FBFR-3) mutation, which is associated with rather  
159 significantly lower grade tumor development. The other one responsible for the mutation is  
160 P53-oncogene and it is associated with the development of high grade tumors. Smoking is  
161 associated with higher grades of bladder cancer development by resulting mutations in both  
162 pathways. Therefore, the prevalence of aggressive tumors in smokers is higher than in non-  
163 smokers. In a study published recently, the rate of high grade tumors in smokers was 26% and  
164 in non-smokers was 13% and this difference was statistically significant ( $p < 0.05$ ) [11]. In our  
165 study, the prevalence of high grade bladder cancer was significantly higher in smoking  
166 patients than non-smokers (91% vs. 7.7%).

167 Age and gender are an important risk factors for bladder cancer. Bladder cancer is detected  
168 more often in men, however, in women the prognosis is worse. Smoking women have shown  
169 an increased risk of invasive bladder cancer compared to smoking men [12]. Bladder cancers

170 are usually middle-aged and / or advanced age disease. Approximately 90% of initially  
171 diagnosed bladder cancer patients are over sixty years of age. However, bladder cancer under  
172 the age of thirty-five is rare. Sturgeon et al. [13] showed that cigarette smoking increased the  
173 risk of muscle-invasive tumor in patients younger than 60 years, and there was no statistically  
174 significant relationship between smoking and stage of the tumor in patients aged 60 years or  
175 older. In our study, it was found that cigarette smoking did not significantly affect the risk of  
176 muscle-invasive tumor in clinically low risk patients. The average age of our study was 66.4  
177 years and 62.7 years in the smoker and non-smoker groups, respectively. We did not detect  
178 any correlation between muscle-invasive tumor and cigarette smoking may be because there  
179 were no female patients in the smoker group and the mean age was over 60 years.

180 The relationship between cigarette smoking and the stage of tumor at initial diagnosis differs  
181 in various studies. Although some studies have reported that cigarette smoking does not affect  
182 the stage and grade of tumor, some other studies have reported that cigarette smoking is  
183 associated with high grade tumors, and in a study cigarette smoking is associated with low  
184 grade tumors. In a recent study by Jiang et al. [12] have reported that the incidence of  
185 advanced stage bladder tumors, especially muscle-invasive bladder tumors, was higher in  
186 smokers. The same study also reported that as smoking duration and smoking intensity  
187 increased, high grade tumors and muscle-invasive tumors were detected twice than low grade  
188 tumors. Nevertheless, Sturgeon et al. [13], who investigated the relationship between cigarette  
189 smoking and the grade of bladder cancer, have found that smoking was strongly associated  
190 with low-grade bladder cancer. Again, in the same study, they have found that high-grade  
191 bladder cancer was twice that low-grade bladder cancer. The authors did not explain the cause  
192 and result relation. Fleshner et al. [14], who reported that smoking did not affect tumor grade  
193 and stage, showed that smokers significantly increased the risk of detecting a tumor as large  
194 as 4 cm. In a recent study by Carpenter [15], he found that there was no significant difference

195 in tumor stage and grade in smokers, but reported that recurrence was higher at the time,  
196 significantly. Su et al. [16], reported that smaller than 3 cm tumors tend to be less grade and  
197 stage than those larger than 3 cm in size. In our study, although the tumor size in both groups  
198 was smaller than 3 cm, it was found that high grade and stage tumors were more prevalent in  
199 the smoker group. These findings suggest that smoking increases the stage and grade of tumor  
200 regardless of its size.

201 The risk of developing bladder cancer is directly related to the duration and intensity of  
202 cigarette smoking [17]. In a study showing the relationship between smoking and bladder  
203 cancer stage and grade, it has been reported that active smokers have higher grades and stages  
204 of bladder cancer compared to those who have never smoked and have quit smoking and  
205 those who have quit smoking have higher stages and grades than those who never smoked.  
206 The duration of smoking and quitting cigarette smoking affects the risk of bladder cancer  
207 [18]. In our study, the duration of smoking was not specified and the effect of the disease on  
208 stage and grade was not investigated. This can be regarded as a limitation of our study.

209 **4.1. Conclusions**

210 Under the light of these data, significant associations were found between cigarette smoking  
211 and pathologically high-grade, high-stage tumors in patients who belong to low risk group.

212

213 **Conflicts of interest**

214 The authors declare no conflict of interest.

215 **Author Contributions**

216 **Conception and design:** Ercan Öğreden and Ural Oğuz.

217 **Administrative support:** Orhan Yalçın, Erhan Demirelli.

218 **Provision of study material or patients:** Ercan Öğreden, Ural Oğuz, Erhan Demirelli, Orhan  
219 Yalçın.

220 **Collection and assembly of data:** Ercan Öğreden and Erhan Demirelli.

221 **Data analysis and interpretation:** Ercan Öğreden and Ural Oğuz.

222 **Manuscript writing:** All authors.

223 **Final approval of manuscript:** All authors.

224 **Appendix**

225 **Table 1.** Mann Whitney U test result on differences between groups in terms of age values.

226 **Table 2.** The relationship between the groups and the variables of the Chi Square Test result.

227

228

229

230

231

232

233

234

235

236

237 **5. References**

238 1. Jemal, A.; Siegel R.; Ward, E.; Murray, T.; Xu, J.; Thun, MJ. Cancer statistics. 2007.  
239 CA Cancer J Clin. 2007, 57, 43-66. <https://doi.org/10.3322/canjclin.57.1.43>.

240 2. Horstmann, M.; Witthuhn, R.; Falk, M.; Stenzl, A. Gender-specific differences in  
241 bladder cancer: a retrospective analysis. Gend Med. 2008, 5, 385-394.  
242 <https://doi.org/10.1016/j.genm.2008.11.002>.

243 3. Delclos, G.L.; Lerner, S.P. Occupational risk factors. Scand J Urol Nephrol Suppl.  
244 2008, 58-63. <https://doi.org/10.1080/03008880802284423>.

245 4. Nilsson, S.; Ullén, A. Chemotherapy-induced bladder cancer. Scand J Urol Nephrol  
246 Suppl. 2008, 89-92. <https://doi.org/10.1080/03008880802291832>.

247 5. Mitra, A.P.; Cote, R.J. Molecular pathogenesis and diagnostics of bladder cancer.  
248 Annu Rev Pathol. 2009, 4, 251-285. <https://doi.org/10.1146/annurev>.

249 6. Brooks, D.R.; Geller, A.C.; Chang, J.; Miller, D.R. Occupation, smoking, and the risk  
250 of high-grade invasive bladder cancer in Missouri. Am J Ind Med. 1992, 21, 699-713.  
251 <https://doi.org/10.1002/ajim.4700210510>.

252 7. Hecht, S.S. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat  
253 Rev Cancer. 2003, 3, 733-744. <https://doi.org/10.1038/nrc1190>.

254 8. Hayes, R.B.; Freidell, G.H.; Hoar Zahm, S.; Cole, P. Are the known bladder cancer  
255 risk factors associated with more advanced bladder cancer? Cancer Causes Control.  
256 1993, 4, 157-162. <https://doi.org/10.1007/BF00053157>.

257 9. Figueroa, J.D.; Middlebrooks, C.D.; Banday, A.R.; Ye, Y.; Garcia-Closas, M.; Chatterjee, N. et al. Identification of a novel susceptibility locus at 13q34 and  
258 refinement of the 20p12.2 region as a multi-signal locus associated with bladder  
259

260 cancer risk in individuals of European ancestry. *Hum Mol Genet.* 2016, 25, 1203-  
261 1214. <https://doi.org/10.1093/hmg/ddv492>.

262 10. Chavan, S.; Bray, F.; Lortet-Tieulent, J.; Goodman, M.; Jemal, A. International  
263 variations in bladder cancer incidence and mortality. *Eur Urol.* 2014, 66, 59-73.  
264 <https://doi.org/10.1016/j.eururo.2013.10.001>.

265 11. Pietzak, E.J.; Malkowicz, S.B. Does quantification of smoking history correlate with  
266 initial bladder tumor grade and stage? *Curr Urol Rep.* 2014, 15, 416.  
267 <https://doi.org/10.1007/s1193>.

268 12. Jiang, X.; Castelao, J.E.; Yuan, J.M.; Stern, M.C.; Conti, D.V.; Cortessis, V.K.; et al.  
269 Cigarette smoking and subtypes of bladder cancer. *Int J Cancer.* 2012, 130, 896-901.  
270 <https://doi.org/10.1002/ijc.26068>.

271 13. Sturgeon, S.R.; Hartge, P.; Silverman, D.T.; Kantor, A.F.; Linehan, W.M.; Lynch, C.;  
272 et al. Associations between bladder cancer risk factors and tumor stage and grade at  
273 diagnosis. *Epidemiology.* 1994, 5, 218-225. <http://www.jstor.org/stable/3702364>.

274 14. Fleshner, N.; Garland, J.; Moadel, A.; Herr, H.; Ostroff, J.; Trambert, R.; et al.  
275 Influence of smoking status on the disease-related outcomes of patients with tobacco-  
276 associated superficial transitional cell carcinoma of the bladder. *Cancer.* 1999, 86,  
277 2337-2345. [https://doi.org/10.1002/\(SICI\)1097-0142\(19991201\).1](https://doi.org/10.1002/(SICI)1097-0142(19991201).1).

278 15. Carpenter, A.A. Clinical experience with transitional cell carcinoma of the bladder  
279 with special reference to smoking. *J Urol.* 1989, 141, 527-528.  
280 [https://doi.org/10.1016/S0022-5347\(17\)40880-9](https://doi.org/10.1016/S0022-5347(17)40880-9).

281 16. Su, X.; Fang, D.; Li, X.; Xiong, G.; Zhang, L.; Hao, H.; et al. The Influence of Tumor  
282 Size on Oncologic Outcomes for Patients with Upper Tract Urothelial Carcinoma after

283 Radical Nephroureterectomy. Biomed Res Int. 2016, 2016, 4368943.

284 <http://dx.doi.org/10.1155/2016/4368943>.

285 17. Brennan, P.; Bogillot, O.; Cordier, S.; Greiser, E.; Schill, W.; Vineis, P.; et al.

286 Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control

287 studies. Int J Cancer. 2000, 86, 289-294. [https://doi.org/10.1002/\(SICI\)1097-0215\(20000415\)133:4<446::AID-IJC28017>3.0.CO;2-1](https://doi.org/10.1002/(SICI)1097-0215(20000415)133:4<446::AID-IJC28017>3.0.CO;2-1).

288

289 18. van Roekel, E.H.; Cheng, K.K.; James, N.D.; Wallace, D.M.; Billingham, L.J.;

290 Murray, P.G.; et al. Smoking is associated with lower age, higher grade, higher stage,

291 and larger size of malignant bladder tumors at diagnosis. Int J Cancer. 2013, 133, 446-

292 454. <https://doi.org/10.1002/ijc.28017>.